Mutations including IDH (IDH1 and IDH2), 1p/19q codeletion, EGFR amplification, amplification of chromosome 7 and loss of chromosome 10 (+7/−10), TERT promoter alteration, ATRX deletion, TP53 positive, and CDKN2A/B deletion are usually used for molecular diagnosis and stratification of most patients with gliomas [2]. The gene discussed is IDH1; the disease is central nervous system cancer.